SENS.L Regulatory News (SENS)

Board changes

Oxford, U.K. 01 March 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the British Clinical AI technology company, is today pleased to announce additions to its Board.

Richard Pye has been appointed as Chief Financial Officer and Executive Director. Richard was previously Sensyne's Chief Investment Officer. Michael Norris, Sensyne's former Interim Chief Financial Officer, and Geoff Race will join the Sensyne Board as Non-Executive Directors. These appointments became effective on 26 February 2021.

Sir Bruce Keogh, Chairman of Sensyne Health, said:

"I am delighted to welcome Richard, Geoff and Michael to the Board of Sensyne. I would like to thank Michael for his excellent service as Interim CFO and I am delighted he has agreed to stay with the business as a Non-Executive Director. These senior appointments, combined with our strong team, will help us boost commercial momentum and accelerate the scaling of the business internationally."

Dr. Richard Pye

Dr. Richard Pye has over 15 years' experience in corporate finance and investor relations in the public market life science sector. Prior to joining Sensyne, Richard was at Summit Therapeutics plc, an AIM and Nasdaq-listed biopharmaceutical company, where he held a number of leadership roles including most recently the position of Vice President of Corporate Affairs and Investor Relations. At Summit, he was involved in a wide range of corporate activities including financial reporting, cross border capital raises, corporate development and strategy, investor communications and corporate governance. Richard holds a PhD in organic chemistry and was a Post-Doctoral Research Associate at the University of Oxford prior to moving into the life sciences industry.

Michael Norris

Michael Norris has served as Sensyne's Interim CFO since March 2020 and has more than 20 years of experience working with public and private companies in the technology and life sciences sectors. Michael is currently also Director and CFO of Beckley Psytech Ltd, a company developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. He has a wealth of CFO and Interim CFO experience having served in those roles for several companies in the UK and US. Michael is a Fellow of the Chartered Institute of Management Accountants.

Geoff Race

Geoff Race is the co-founder, EVP, CFO, and CBO of Nasdaq listed biopharmaceutical company Minerva Neurosciences Inc. He has more than 20 years of experience as CEO and CFO in the life science industry, including roles at Funxional Therapeutics Ltd, PanGenetics BV and CareX SA. Geoff is also a Non-Executive Director at Nasdaq listed F-star Therapeutics Inc. and Chairman and co-founder of London based consumer behaviour data providers, Huq Industries Ltd. Geoff received an MBA from Durham University Business School, UK, and is a Fellow of the Chartered Institute of Management Accountants.

Regulatory Disclosures

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Dr. Richard Joseph Pye (age 44)

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Mr Pye.

Michael John Norris (age 56)

Current Directorships or Partnerships:

· Beckley Psytech Ltd

· Rivertime Corporate Finance Ltd

· Norris Biomedical Services Ltd

· Secret Saviours Ltd

· Rapid Rhythm Ltd

Directorships or partnerships held within the past 5 years:

· Sporting Club Leigh Ltd

· MedeTrax Ltd

· Biosensors Ltd

· Alchemy Pharmatech Ltd

· TTS Pharma Ltd

· Albert Medical Devices Ltd

· Michael Norris Consultancy Limited

Michael Norris is an experienced financial consultant and earlier in his career he was involved in a number of financial turnaround situations. He was a director of i3-Group Limited from 2011 until 2013, less than 12 months prior to the company entering into voluntary liquidation in 2014 with no shortfall to creditors. The company was dissolved and subsequently restored. Michael has no association with the similarly named i3 Group Limited. Michael was CEO of Micap plc (and its wholly owned subsidiaries Applied Analysis Limited, Micap Ingredients Limited and F.S.M. Technologies Limited) which went into administration in November 2008 with a shortfall to creditors of approximately £1.2 million. Michael was a director of Rivertime Restaurants Limited within the 12 months preceding its administration and £65,000 shortfall to creditors.

Michael Norris holds 27,777 shares in the Company, representing 0.02% of the issued share capital.

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Mr Norris.

Geoffrey Robin Race (age 60):

Current Directorships or Partnerships:

· Minerva Neurosciences Inc (CFO & CBO)

· F-Star Therapeutics Inc

· F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H

· Huq Industries Ltd

Directorships or partnerships held within the past 5 years:

· F-Star Biotechnology Ltd

Geoff Race was a director of All Wheel Drive Limited, a company under common ownership with Artix Limited, when it went into receivership in 1992. Records indicate there may have been a shortfall to creditors.

There is no further information required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules in respect of Mr Race.

-ENDS-

For more information please contact:

About Sensyne Health www.sensynehealth.com.

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. This work uses data provided by patients and collected by the NHS as part of their care and support. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).